Navigation Links
Study Suggests Strattera Improved ADHD Symptoms in Patients With,Comorbid Alcohol Abuse

(AISRS). At study endpoint of 12 weeks the reduction of ADHD symptoms in subjects with comorbid alcohol abuse disorder was significantly improved for the Strattera group (-13.63) relative to the placebo group (-8.31). The study showed no significant difference in time to alcohol abuse relapse between the Strattera and placebo treatment groups. However, an exploratory post hoc analysis undertaken to examine drinking throughout the study suggested a positive trend in reducing cumulative heavy drinking days by 26 percent in the treated group compared to placebo, though more study is needed to determine the validity of this specific finding.

ADHD is a potential risk factor for developing alcohol abuse problems.(1) In addition, alcohol abuse problems may be more common among people with ADHD than among those without ADHD. According to data from the National Comorbidity Survey Replication, nearly three times the number of individuals with ADHD (12 percent) have comorbid alcohol abuse or dependence disorder compared to the general population (4.4 percent).(2)

Strattera was generally well-tolerated in this study. Adverse events were similar to those noted in previous trials and discontinuations due to adverse events were not different between groups. The most common adverse events reported were nausea, dry mouth, decreased appetite, dizziness, fatigue, constipation and urinary hesitation. Discontinuation rates reported in this study from adverse events were 9.7 percent for the Strattera group compared to 2.7 percent for the placebo group.

Methods

In this randomized, placebo-controlled study, 72 patients received Strattera (25-100 mg daily) and 75 patients received placebo for approximately 12 weeks, at which time, their ADHD symptoms were measured using the AISRS. Study subjects were recently abstinent from alcohol at least four days before study randomization and included 125 men and 22 women, mean age approximately 34 years-old.

The stu
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:8/28/2015)... LONDON , August 28, 2015 ... approach seamlessly connects people, technologies and care protoc ... improving outcomes and the cost of healthcare delivery   ... PHIA) today announced its presence at  ESC Congress 2015 , where ... Model A.I. , EchoNavigator and IntelliSpace Cardiovascular, that connect people ...
(Date:8/27/2015)... Va. , Aug. 27, 2015  The ... the Food and Drug Administration,s (FDA,s) draft guidance ... reference products and biosimilars, to bear a nonproprietary ... AMCP has been seeking a decision from the ... 18 diverse health care stakeholders urging the agency ...
(Date:8/27/2015)... DURECT Corporation (Nasdaq: DRRX ) announced ... upcoming healthcare conferences.  , James ... the Rodman & Renshaw Investment Conference on Thursday, September ... being held at the St. Regis Hotel in ... webcast of the presentation will be available by accessing ...
Breaking Medicine Technology:Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2DURECT to Participate in Upcoming Healthcare Conferences 2
... FOLD ) today announced that John F. Crowley ... Chairman in order to devote more time to interests related ... role as Executive Chairman, Mr. Crowley will continue to perform ... will advise the current Amicus management team on corporate strategy ...
... The board of directors of Eli Lilly and Company (NYSE: ... second quarter of 2011 of $0.49 a share on outstanding ... 10, 2011 to shareholders of record at the close of ... innovation-driven corporation, is developing a growing portfolio of pharmaceutical products ...
Cached Medicine Technology:Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman 2
(Date:8/28/2015)... ... August 28, 2015 , ... Mendon, IL, home of the ... and good people, all for a good cause. In its second year, the “Music ... more by Best Drug Rehabilitation. The “Mission” of “Music With A Mission” is to ...
(Date:8/28/2015)... ... 28, 2015 , ... Healthpointe clinics throughout Southern California ... diving. The act of recreational diving exposes the body to extreme changes ... vital that all recreational and professional divers undergo regular comprehensive scuba physicals. Healthpointe’s ...
(Date:8/28/2015)... ... August 28, 2015 , ... The newest therapy to receive orphan drug status ... any time soon, according to educational website Surviving Mesothelioma. Click here to read ... designation for mesothelioma last week from the FDA, will now head into Phase I ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... is pleased to welcome TJS Insurance Group as its newest Partner Firm. Founded ... guides them and keeps them focused on their goals. Within the past 10 ...
(Date:8/28/2015)... ... August 28, 2015 , ... External Counterpulsation, also known ... Clinic is now selling External Counterpulsation (EECP or ECP) machines with a full clinic ... has been in business since 2007 helping people prevent and reverse heart disease ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2
... microscope, scientists have tried to visualize smaller and smaller structures ... bacteria and viruses. Now, researchers at the National Institute ... the National Institutes of Health, have developed a new way ... before. Their findings are reported in the Jan. 13 ...
... (HealthDay News) -- The chemotherapy used to treat a form ... the return of the disease within years, a new study ... who thought chemotherapy drugs could disrupt DNA through mutations and ... medications. "Chemotherapy drugs are absolutely necessary to get ...
... Jefferson,s Kimmel Cancer Center has started a ... cancer chemotherapy drug to extend survival, Cabazitaxel, in ... approach could improve disease control and eventually survival ... single-center, open-label, non-randomized Phase I study ...
... Using two cell surface markers found to be ... researchers at Moffitt Cancer Center, working with colleagues ... imaging probes that can non-invasively detect breast cancer ... breast cancer patients invasive and unreliable sentinel lymph ...
... women are scarce leads men to become impulsive, save less, ... of Minnesota,s Carlson School of Management. "What we see ... become more competitive. They compete more for access to mates," ... Carlson School and lead author of the study. "How do ...
... language are quicker at recognizing and interpreting body language than ... Davis and UC Irvine. The work suggests that deaf ... visual traits in the actions of others, an ability that ... screening. "There are a lot of anecdotes about deaf ...
Cached Medicine News:Health News:NIH scientists identify novel approach to view inner workings of viruses 2Health News:DNA Damage From Chemo May Help Spur Leukemia's Return 2Health News:Cabazitaxel with radiation and hormone therapy may improve prostate cancer survival 2Health News:Researchers find new, noninvasive way to identify lymph node metastasis 2Health News:A scarcity of women leads men to spend more, save less 2Health News:A scarcity of women leads men to spend more, save less 3Health News:Deaf sign language users pick up faster on body language 2
10 mm angled blade with notches on sides and tip. Round knurled handle with polished finish....
1 mm wide by 33 mm long malleable blade. Flat serrated handle with polished finish....
Lasik spatula useful for protecting a previous flap for retreatment to lift and smooth the corneal flap....
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 130o....
Medicine Products: